Table 1

Characteristics of the samples at each time point

Time pointsT1T2T3T4T5T6T7
Sample size1161451059591107137
Clinic population size220245285286315336355
Men45 (39%)63 (43%)45 (43%)39 (41%)33 (36%)51 (48%)61 (44%)
Women71 (61%)82 (57%)60 (57%)56 (59%)58 (64%)56 (52%)76 (56%)
Age, mean (SD)
[Range]
25.1 (6.7)
[16–50]
24.7 (7.3)
[14–51]
26.3 (7.8)
[14–53]
28.6 (7.3)
[16–51]
29.7 (8.1)
[18–50]
31.6 (7.5)
[20–55]
33.7 (7.8)
[22–57]
FEV1%, mean (SD)
[Range]
58.5% (24.4)
[14.0–133.0%]
59.6% (23.9)
[12.0–128.0%]
60.8% (24.4)
[16.0–128.0%]
59.6% (22.9)
[20.0–113.0%]
57.0% (24.8)
[16.0–109.0%]
57.3% (23.9)
[14.0–119.0%]
56.9% (23.3)
[14.0–114.0%]
 Mild disease, N (%)41 (35%)55 (38%)40 (38%)30 (32%)30 (33%)32 (30%)38 (28%)
 Moderate disease, N (%)42 (36%)58 (40%)39 (37%)44 (46%)32 (35%)46 (43%)63 (46%)
 Severe disease, N (%)33 (29%)32 (22%)26 (25%)21 (22%)29 (32%)29 (27%)36 (26%)
BMI, mean (SD)
[Range]
21.4 (3.1)
[15.6–30.2]
21.5 (2.9)
[16.0–30.1]
21.9 (3.1)
[15.1–33.1]
22.0 (2.7)
[16.3–29.2]
22.0 (3.2)
[13.3–33.7]
21.9 (3.2)
[16.8–34.2]
21.3 (3.2)
[16.1–33.8]
IV access device47 (41%) 72 (50%)50 (48%)46 (48%)51 (56%)66 (62%)85 (62%)
B cepacia complex7 (6%)13 (9%)10 (10%)10 (11%)4 (4%)10 (9%)8 (6%)
CF-related diabetes26 (22%)49 (34%)38 (36%)32 (34%)36 (40%)49 (46%)69 (50%)
Oral nutritional supplements44 (38%)45 (31%)36 (34%)25 (26%)30 (33%)37 (35%)44 (32%)
Enteral tube feeds24 (21%)27 (19%)10 (10%)16 (17%)9 (10%)16 (15%)26 (19%)
Post-transplant11 (9%)14 (10%)12 (11%)17 (18%)14 (15%)13 (12%)18 (13%)
  • BMI, body mass index; CF, cystic fibrosis; FEV1%, forced expiratory volume in 1 s; IV, intravenous.